Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer.
Sandra Ortiz-CuaranLaura MezquitaAurélie SwalduzMihalea AldeaJulien MazieresCamille LeonceCecile JoveletAnne PradinesVirginie AvrillonWashington R Chumbi FloresLudovic LacroixYohann LoriotVirginie WesteelMaud Ngo-CamusClaire TissotChristine RaynaudRadj GervaisEtienne G C BrainIsabelle MonnetEtienne Giroux LeprieurCaroline CaramellaCeline Mahier-Aït OukhatarNatalie Hoog-LabouretFrank de KievitKaren HowarthClive MorrisEmma GreenLuc FribouletSylvie ChabaudJean-François GuichouMaurice PérolBenjamin BesseJean Yves BlayPierre SaintignyDavid PlanchardPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
ctDNA sequencing is clinically relevant for the detection of BRAF-activating mutations and the identification of alterations potentially related to resistance to BRAF-TT in BRAF-mutant NSCLC.